Literature DB >> 15496202

HLA-E polymorphism in patients with nasopharyngeal carcinoma.

N Hirankarn1, I Kimkong, A Mutirangura.   

Abstract

Nasopharyngeal carcinoma (NPC) has been known to be associated with HLA class I region. The aim of this study was to investigate the association between HLA-E and genetic susceptibility to nasopharyngeal carcinogenesis by comparing the frequencies of HLA-E alleles in 100 Thai NPC patients and 100 healthy controls. HLA-E typing was performed by means of polymerase chain reaction-sequence-specific oligonucleotide probe method. The frequency of the HLA-E*0103 allele and HLA-E*0103, 0103 genotype, but not others, was increased in NPC patients, compared to controls. This observation suggests a possible role for HLA-E in NPC development, possibly via natural killer cell or cytotoxic lymphocyte function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496202     DOI: 10.1111/j.1399-0039.2004.00311.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  11 in total

Review 1.  Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors.

Authors:  Allan Hildesheim; Cheng-Ping Wang
Journal:  Semin Cancer Biol       Date:  2012-01-25       Impact factor: 15.707

2.  HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines haplotype structure and variation spanning the nonclassical class I genes.

Authors:  Chul-Woo Pyo; Luke M Williams; Yuki Moore; Hironobu Hyodo; Shuying Sue Li; Lue Ping Zhao; Noriko Sageshima; Akiko Ishitani; Daniel E Geraghty
Journal:  Immunogenetics       Date:  2006-03-29       Impact factor: 2.846

3.  Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.

Authors:  Takahiro Kamiya; See Voon Seow; Desmond Wong; Murray Robinson; Dario Campana
Journal:  J Clin Invest       Date:  2019-03-12       Impact factor: 14.808

4.  Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer.

Authors:  Zi-Jun Zhen; Jia-Yu Ling; Yue Cai; Wen-Biao Luo; You-Jian He
Journal:  Med Oncol       Date:  2013-02-03       Impact factor: 3.064

5.  Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer.

Authors:  Hui Zheng; Renquan Lu; Suhong Xie; Xuemei Wen; Hongling Wang; Xiang Gao; Lin Guo
Journal:  Cancer Sci       Date:  2015-04-13       Impact factor: 6.716

Review 6.  HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia.

Authors:  Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

7.  The genetic contribution of HLA-E*01:03 and HLA-E*01:03-G*01:01 to Posner-Schlossman syndrome in southern Chinese.

Authors:  Xiaosheng Huang; Yunping Xu; Wenchieh Chen; Tianhui Zhu; Liumei He; Songxing Wang; Shiming Peng; Shaoyi Mei; Yan Wang; Jun Zhao
Journal:  Ann Transl Med       Date:  2019-12

8.  HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02.

Authors:  Paloma Martín; Isabel Krsnik; Belen Navarro; Mariano Provencio; Juan F García; Carmen Bellas; Carlos Vilches; Natalia Gomez-Lozano
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

9.  Human Leukocyte Antigen-E Alleles are Associated with Hepatitis C Virus, Torque Teno Virus, and Toxoplasma Co-infections but are not Associated with Hepatitis B Virus, Hepatitis D Virus, and GB Virus C Co-infections in Human Immunodeficiency Virus Patients.

Authors:  Afiono Agung Prasetyo; Ruben Dharmawan; Irvan Raharjo
Journal:  J Glob Infect Dis       Date:  2016 Apr-Jun

10.  Association between HLA-E gene polymorphism and unexplained recurrent spontaneous abortion (RSA) in Iranian women.

Authors:  Maryam Fotoohi; Nasrin Ghasemi; Seyed Ali Mirghanizadeh; Mahmood Vakili; Morteza Samadi
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.